APA (7th ed.) Citation

P, T., OS, A., NM, R., BE, B., A, K., A, G., . . . FJ, H. (2022). Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer, 128(8), 1595. https://doi.org/10.1002/cncr.34106

Chicago Style (17th ed.) Citation

P, Torka, et al. "Ofatumumab Plus HyperCVAD/HD-MA Induction Leads to High Rates of Minimal Residual Disease Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma: Results of a Phase 2 Study." Cancer 128, no. 8 (2022): 1595. https://doi.org/10.1002/cncr.34106.

MLA (9th ed.) Citation

P, Torka, et al. "Ofatumumab Plus HyperCVAD/HD-MA Induction Leads to High Rates of Minimal Residual Disease Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma: Results of a Phase 2 Study." Cancer, vol. 128, no. 8, 2022, p. 1595, https://doi.org/10.1002/cncr.34106.